person · Reporting owner

Morris Richard Steven

Disclosed activity across 3 companies

Tapewire entity: 89773
SEC CIK: 0001432303

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Carisma Therapeutics Inc.CARM · Entity 74418	Chief Financial Officer	June 17, 2024	June 18, 2024
Passage BIO, Inc.PASG · Entity 7829	Chief Financial Officer	May 21, 2021	May 21, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Carisma Therapeutics Inc.

Report date June 17, 2024 · Filed June 18, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2034-06-17	Direct	85,000	Reported balance After 2024-06-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-06-17 · Grant · Acquired 85,000 · Balance 85,000 F1: The shares underlying this option vest over two years, with 50% of the shares vesting on June 17, 2025 and the remaining 50% of the shares vesting on June 17, 2026, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option vest over two years, with 50% of the shares vesting on June 17, 2025 and the remaining 50% of the shares vesting on June 17, 2026, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date.

Passage BIO, Inc.

Report date May 21, 2021 · Filed May 21, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	5,454	Reported balance After 2021-05-21 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2021-05-21 · Purchase · Acquired 2,171 · Balance 5,454 F1: Includes 2020 Employee Stock Purchase Plan allocations of 1,495 shares that occurred since the date of the reporting person's last ownership report.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 2020 Employee Stock Purchase Plan allocations of 1,495 shares that occurred since the date of the reporting person's last ownership report.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Vitae Pharmaceuticals, Inc

Report date October 25, 2016 · Filed October 25, 2016

Section 16 reporting ended · disclosed 2016-10-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2016-10-25 transaction · row 1 1 source row Row 1 · 2016-10-25 · Disposition to issuer · Disposed 828 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., whereby, immediately prior to the effective time of the merger contemplated therein, all issued and outstanding shares of Issuer common stock were converted into the right to receive $21.00 per share in cash and, when so converted, automatically cancelled.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.29 · Expires 2024-06-24	Direct	Reported balance After 2016-10-25 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2016-10-25 · Disposition to issuer · Disposed 152,173 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such option. F3: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on May 19, 2014 (the "Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.40 · Expires 2025-02-13	Direct	Reported balance After 2016-10-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-10-25 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such option. F4: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on February 13, 2016 (the "February 2016 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the February 2016 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.28 · Expires 2025-08-14	Direct	Reported balance After 2016-10-25 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-10-25 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such option. F5: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on August 14, 2016 (the "August 2016 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the August 2016 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.58 · Expires 2026-02-15	Direct	Reported balance After 2016-10-25 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2016-10-25 · Disposition to issuer · Disposed 27,500 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such option. F6: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on February 15, 2017 (the "February 2017 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the February 2017 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.78 · Expires 2026-08-14	Direct	Reported balance After 2016-10-25 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2016-10-25 · Disposition to issuer · Disposed 27,500 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such option. F7: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on August 15, 2017 (the "August 2017 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the August 2017 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., whereby, immediately prior to the effective time of the merger contemplated therein, all issued and outstanding shares of Issuer common stock were converted into the right to receive $21.00 per share in cash and, when so converted, automatically cancelled.

F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such option.

F3: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on May 19, 2014 (the "Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

F4: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on February 13, 2016 (the "February 2016 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the February 2016 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

F5: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on August 14, 2016 (the "August 2016 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the August 2016 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

F6: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on February 15, 2017 (the "February 2017 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the February 2017 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

F7: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on August 15, 2017 (the "August 2017 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the August 2017 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 17, 2024 Filed Jun 18, 2024 19:08 UTC	Carisma Therapeutics Inc. CARM · Entity 74418	GrantStock Option (Right to Buy) · Derivative	85,000	$0.00 Strike: $1.03	$0.00	Disclosure SEC source: 0001104659-24-072978 · tm2417501-3_4seq1.xml · derivative · entry 1 Morris Richard Steven · CIK 0001432303 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2034-06-17 F1 · derivative.exercise_date: The shares underlying this option vest over two years, with 50% of the shares vesting on June 17, 2025 and the remaining 50% of the shares vesting on June 17, 2026, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date. Read SEC document
January 31, 2024 Filed Feb 2, 2024 16:53 UTC	Carisma Therapeutics Inc. CARM · Entity 74418	GrantStock Option (Right to Buy) · Derivative	170,500	$0.00 Strike: $2.10	$0.00	Disclosure SEC source: 0001104659-24-010110 · tm245034-3_4seq1.xml · derivative · entry 1 Morris Richard Steven · CIK 0001432303 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,500 Underlying: Common Stock · 170,500 shares Expires 2034-01-31 F1 · derivative.exercise_date: The shares underlying this option vest over four years in equal monthly installments, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date. Read SEC document
June 06, 2023 Filed Jun 8, 2023 18:18 UTC	Carisma Therapeutics Inc. CARM · Entity 74418	GrantStock Option (Right to Buy) · Derivative	238,000	$0.00 Strike: $7.25	$0.00	Disclosure SEC source: 0001104659-23-069501 · tm2318219-5_4seq1.xml · derivative · entry 1 Morris Richard Steven · CIK 0001432303 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,000 Underlying: Common Stock · 238,000 shares Expires 2033-06-06 F1 · derivative.exercise_date: The shares underlying this option vest over four years, with 25% of the shares vesting on June 6, 2024 and the remaining shares vesting over the next three years thereafter in equal monthly installments, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date. Read SEC document
March 07, 2023 Filed Mar 9, 2023 21:26 UTC	Carisma Therapeutics Inc. CARM · Entity 74418	GrantStock Option (Right to Buy) · Derivative	331,114	Not disclosed Strike: $1.46	Not disclosed	Disclosure SEC source: 0001104659-23-030749 · tm238905-9_4seq1.xml · derivative · entry 1 Morris Richard Steven · CIK 0001432303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,114 Underlying: Common Stock · 331,114 shares Expires 2031-05-31 F1 · price: In connection with the merger of Sesen Bio, Inc. ("Sesen Bio") and private company CARISMA Therapeutics Inc. ("Carisma"), pursuant to the Agreement and Plan of Merger and Reorganization dated as of September 20, 2022, as amended by the First Amendment thereto dated as of December 29, 2022 and the Second Amendment thereto dated as of February 13, 2023 (as amended, the "Merger Agreement"), which closed on March 7, 2023 (the "Closing"), (i) each share of Carisma common stock was converted into the right to receive 1.8994 shares of Sesen Bio common stock (the "Exchange Ratio") and (ii) each outstanding and unexercised option to purchase shares of Carisma common stock converted into an option to purchase shares of Sesen Bio common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. F2 · price: The Exchange Ratio gives effect to the 1-for-20 reverse stock split of Sesen Bio's common stock. On the Closing date, the closing price of Sesen Bio common stock was $0.6288 (unadjusted). Upon Closing, Sesen Bio was renamed "Carisma Therapeutics Inc." F3 · derivative.exercise_date: The shares underlying this option vest over four years, with 25% of the shares vested on June 1, 2022 and the remaining shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document
May 21, 2021 Filed May 21, 2021 18:09 UTC	Passage BIO, Inc. PASG · Entity 7829	PurchaseCommon Stock	2,171	$13.82	$29,999.53	Disclosure SEC source: 0001209191-21-035059 · doc4.xml · nonDerivative · entry 1 Morris Richard Steven · CIK 0001432303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,454 F1 · balance_after: Includes 2020 Employee Stock Purchase Plan allocations of 1,495 shares that occurred since the date of the reporting person's last ownership report. Read SEC document
February 16, 2021 Filed Feb 18, 2021 19:33 UTC	Passage BIO, Inc. PASG · Entity 7829	GrantStock Option (right to buy) · Derivative	50,000	$0.00 Strike: $21.85	$0.00	Disclosure SEC source: 0001209191-21-012169 · doc4.xml · derivative · entry 2 Morris Richard Steven · CIK 0001432303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-02-15 F2 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 16, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
March 03, 2020 Filed Mar 3, 2020 18:44 UTC	Passage BIO, Inc. PASG · Entity 7829	PurchaseCommon Stock	400	$18.00	$7,200.00	Disclosure SEC source: 0001209191-20-015629 · doc4.xml · nonDerivative · entry 1 Morris Richard Steven · CIK 0001432303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 Read SEC document
February 27, 2020 Filed Mar 2, 2020 17:46 UTC	Passage BIO, Inc. PASG · Entity 7829	GrantEmployee Stock Option (Right to Buy) · Derivative	74,311	$0.00 Strike: $18.00	$0.00	Disclosure SEC source: 0001209191-20-014685 · doc4.xml · derivative · entry 1 Morris Richard Steven · CIK 0001432303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,311 Underlying: Common Stock · 74,311 shares Expires 2030-02-27 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on February 27, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 27, 2024, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:31 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	27,500	$12.22 Strike: $8.78	$336,050.00	Disclosure SEC source: 0001104659-16-151938 · a4.xml · derivative · entry 6 Morris Richard Steven · CIK 0001432303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,500 shares Expires 2026-08-14 F2 · shares: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such option. F7 · derivative.exercise_date: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on August 15, 2017 (the "August 2017 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the August 2017 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:31 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	27,500	$12.42 Strike: $8.58	$341,550.00	Disclosure SEC source: 0001104659-16-151938 · a4.xml · derivative · entry 5 Morris Richard Steven · CIK 0001432303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,500 shares Expires 2026-02-15 F2 · shares: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such option. F6 · derivative.exercise_date: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on February 15, 2017 (the "February 2017 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the February 2017 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:31 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	15,000	$12.72 Strike: $8.28	$190,800.00	Disclosure SEC source: 0001104659-16-151938 · a4.xml · derivative · entry 4 Morris Richard Steven · CIK 0001432303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2025-08-14 F2 · shares: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such option. F5 · derivative.exercise_date: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on August 14, 2016 (the "August 2016 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the August 2016 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:31 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	15,000	$6.60 Strike: $14.40	$99,000.00	Disclosure SEC source: 0001104659-16-151938 · a4.xml · derivative · entry 3 Morris Richard Steven · CIK 0001432303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2025-02-13 F2 · shares: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such option. F4 · derivative.exercise_date: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on February 13, 2016 (the "February 2016 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the February 2016 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:31 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	152,173	$15.71 Strike: $5.29	$2,390,637.83	Disclosure SEC source: 0001104659-16-151938 · a4.xml · derivative · entry 2 Morris Richard Steven · CIK 0001432303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 152,173 shares Expires 2024-06-24 F2 · shares: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such option. F3 · derivative.exercise_date: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on May 19, 2014 (the "Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:31 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerCommon Stock	828	$21.00	$17,388.00	Disclosure SEC source: 0001104659-16-151938 · a4.xml · nonDerivative · entry 1 Morris Richard Steven · CIK 0001432303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., whereby, immediately prior to the effective time of the merger contemplated therein, all issued and outstanding shares of Issuer common stock were converted into the right to receive $21.00 per share in cash and, when so converted, automatically cancelled. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.